Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Monday, November 13, 2023
October 31 2023 - 8:00AM
Aspira Women’s Health Inc. (“Aspira”), a bio-analytical
company focused on the development and commercialization of women’s
health diagnostic tools for gynecologic diseases, today announced
that the company will report its financial results for the three
months ended September 30, 2023 on Monday, November 13, 2023.
Management will also host a conference call with investors to
discuss financial results and provide a corporate update at 4:30
p.m. Eastern Time. Details for the call are as follows:
Conference
call & Webcast Details: |
Date: |
Monday, November 13 |
Time: |
4:30 p.m. Eastern Time |
Toll Free: |
1-877-407-4018 |
International: |
1-201-689-8471 |
Webcast: |
click HERE |
Call me™: |
click HERE |
|
|
Participants can use Guest dial-in numbers above and be answered
by an operator OR participants can click the Call me™ link for
instant telephone access to the event. The Call me™ link will
be made active 15 minutes prior to the scheduled start time.
A replay of the webcast will also be available on the Events
& Presentation page of the Aspira Women’s Health Investor
Relations website.
About Aspira Women’s Health Inc. Aspira
Women’s Health Inc. is transforming women’s gynecological health
with the discovery, development, and commercialization of
innovative testing options for women of all races and ethnicities,
starting with ovarian cancer.
Our ovarian cancer risk assessment portfolio is marketed to
healthcare providers as OvaSuiteSM, which includes OvaWatchSM, a
non-invasive, blood-based test intended for use in the initial
clinical assessment of ovarian cancer risk in women with benign or
indeterminate adnexal masses for which surgical intervention may be
either premature or unnecessary. With a negative predictive value
(NPV) of 99%, OvaWatch allows physicians to confidently rule out
ovarian cancer malignancy and choose the appropriate clinical
management for the right patient at the right time.
Ova1Plus® combines our FDA-cleared products, Ova1® and
Overa®, to detect risk of ovarian malignancy in women with adnexal
masses planned for surgery.
EndoCheckSM, Aspira’s first-of-its-kind non-invasive diagnostic
test for endometriosis, is currently in development. Visit our
website for more information at www.aspirawh.com.
Investor Relations
Contact:Monique Kosse Managing DirectorLifeSci Advisors,
LLCTel: 212-915-3820
Aspira Womans Health (NASDAQ:AWH)
Historical Stock Chart
From Apr 2024 to May 2024
Aspira Womans Health (NASDAQ:AWH)
Historical Stock Chart
From May 2023 to May 2024